Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • J&J passes asbestos...

    J&J passes asbestos test, allowed to make baby powder in India

    Farhat NasimWritten by Farhat Nasim Published On 2019-03-01T14:28:50+05:30  |  Updated On 13 Aug 2021 2:59 PM IST

    NEW DELHI: In a major relief to Johnson & Johnson(J&J), no asbestos was found in the baby powder manufactured in Baddi and Mulund plants. The government of India conducted sample tests after allegations of presence of asbestos in its baby powder. However, no trace of asbestos was detected and the company has recently resumed production of its baby powder.


    "Johnson & Johnson has resumed production of its Johnson's Baby Powder at plants in Baddi and Mulund, after government sanctioned testing reaffirmed that the product does not contain asbestos," J&J said in a statement to Reuters.


    Also Read: U.S. senator asks J&J for documents on talc, baby powder safety


    Reuters reported earlier on Thursday that the regulator had not found any asbestos in the company's talc, citing sources familiar with the matter.


    The regulator and its counterparts in Indian states launched an investigation into J&J's Baby Powder following a Reuters report in December that the firm knew for decades that cancer-causing asbestos could be found in the product.


    Also Read: After damaging Reuters report, J&J doubles down on talc safety message


    J&J has described the Reuters article as "one-sided, false and inflammatory".


    The Indian regulator wrote to the U.S. company in December asking it to stop using the "huge quantities" of raw materials stocked in its plants in northern and western India until test results proved they were free of asbestos.


    "In recent months, regulatory authorities from Singapore, Thailand, Saudi Arabia, Jordan, Kuwait, and Egypt have also reaffirmed the purity of Johnson & Johnson's talc," J&J said.


    Also Read: Another trouble for J&J: CDSCO seize samples of baby products for testing

    asbestos fibresAsbestos scarebaby powdercancer causing asbestosCDSCOCentral Drug Testing LaboratoryCentral Drugs Standard Control OrganizationDCGIDrug Controller General of IndiaFaulty hip implantsFDAJ&JJ&J baby powderJohnson and Johnsonlung cancerovarian cancerUnion Health Ministr
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok